A systematic review of tests for lymph node status in primary endometrial cancer by Selman, Tara J et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Women's Health
Open Access Research article
A systematic review of tests for lymph node status in primary 
endometrial cancer
Tara J Selman*1, Christopher H Mann1, Javier Zamora2 and Khalid S Khan1
Address: 1Department of Reproductive and Child Health, university of Birmingham, Birmingham Women's Hospital, Birmingham, UK and 
2Clinical Biostatistics Unit, Hospital Ramón y Cajal. CIBER Epidemiologia y Salud Publica (CIBERESP). Madrid, Spain
Email: Tara J Selman* - taraselman@blueyonder.co.uk; Christopher H Mann - c.h.mann@bham.ac.uk; Javier Zamora - javier.zamora@hrc.es; 
Khalid S Khan - k.s.khan@bham.ac.uk
* Corresponding author    
Abstract
Background: The lymph node status of a patient is a key determinate in staging, prognosis and
adjuvant treatment of endometrial cancer. Despite this, the potential additional morbidity
associated with lymphadenectomy makes its role controversial. This study systematically reviews
the accuracy literature on sentinel node biopsy; ultra sound scanning, magnetic resonance imaging
(MRI) and computer tomography (CT) for determining lymph node status in endometrial cancer.
Methods: Relevant articles were identified form MEDLINE (1966–2006), EMBASE (1980–2006),
MEDION, the Cochrane library, hand searching of reference lists from primary articles and
reviews, conference abstracts and contact with experts in the field. The review included 18 relevant
primary studies (693 women). Data was extracted for study characteristics and quality. Bivariate
random-effect model meta-analysis was used to estimate diagnostic accuracy of the various index
tests.
Results: MRI (pooled positive LR 26.7, 95% CI 10.6 – 67.6 and negative LR 0.29 95% CI 0.17 –
0.49) and successful sentinel node biopsy (pooled positive LR 18.9 95% CI 6.7 – 53.2 and negative
LR 0.22, 95% CI 0.1 – 0.48) were the most accurate tests. CT was not as accurate a test (pooled
positive LR 3.8, 95% CI 2.0 – 7.3 and negative LR of 0.62, 95% CI 0.45 – 0.86. There was only one
study that reported the use of ultrasound scanning.
Conclusion: MRI and sentinel node biopsy have shown similar diagnostic accuracy in confirming
lymph node status among women with primary endometrial cancer than CT scanning, although the
comparisons made are indirect and hence subject to bias. MRI should be used in preference, in light
of the ASTEC trial, because of its non invasive nature.
Background
Endometrial cancer is a cancer of the developed world. In
Europe it is the most common gynaecological cancer and
the fourth most common female cancer after breast, lung
and colon cancer [1]. Despite the frequency of this disease
the treatment of this cancer, especially in its early stage
remains controversial. In 1988 FIGO changed the staging
of endometrial cancer to include pelvic and paraaortic
lymphadenectomy in acceptance that the lymph node sta-
tus is one of the most important prognostic factors for a
patient [2]. This led to large variations in practice through-
out the UK and Europe. A Study of Gynaecological Oncol-
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ogists in Western Europe revealed only 24.4% performed
lymphadenectomy and that despite it's inclusion as part
of FIGO staging most reserved it for specific pathological
conditions [3].
Advocates for lymphadenectomy demonstrate that it
allows precise determination of prognosis, accurate tailor-
ing of adjuvant therapy, and may potentially provide a
small survival advantage [4]. Others argue that routine
lymphadenectomy is associated with an increased opera-
tive time averaging an extra 30 minutes, an increased risk
of intraoperative complications and that lymphadenec-
tomy is not necessary in women with good prognostic fac-
tors that are at low risk of lymph node involvement.
Women with stage 1a-1c disease have less than 0–15%
chance of lymph node metastasis.
In light of the controversy surrounding the benefits and
risks of lymphadenectomy in patients with endometrial
cancer there is increasing interest in minimal and non
invasive techniques to determine their lymph node status.
Potentially the introduction of a reliable technique could
direct the most appropriate patient treatment without the
unnecessary risk of lymphadenectomy. As in other cancers
studies have investigated the use of imaging techniques
and sentinel node biopsy, but the accuracy of these
modalities has not been adequately assessed. We system-
atically reviewed the evidence for the accuracy of mini-
mally invasive and non invasive tests to determine the
lymph node status in women with primary endometrial
cancer.
Methods
We used widely recommended methodology in the design
of our protocol for the systematic review of the literature
[5,6].
Sources
Our search attempted to capture all the studies that
reported the diagnostic accuracy of sentinel node biopsy,
positron emission tomography (PET), magnetic reso-
nance imaging (MRI), computer tomography (CT) and
ultrasound scanning for the detection of lymphatic spread
in primary endometrial cancer. Bibliographic databases
MEDLINE (1966–2006), EMBASE, Cochrane Library
(issue II, 2006) and MEDION (1980–2006) were
searched without language restrictions. The search strat-
egy used relevant medical subheadings (MeSH), text
words and word variants for endometrial cancer and com-
bined these with the terms for the index tests and lym-
phadenopathy (see Additional file 1). Hand searches of
reference lists from primary articles and other reviews
were carried out to identify manuscripts missed by elec-
tronic searching. Experts in the field were contacted for
unpublished studies and conference abstracts were
reviewed.
Study selection and data extraction
The selection of studies involved a two-stage process and
two reviewers (TJS, CHM). The electronic searches were
examined and complete manuscripts of potentially rele-
vant citations retrieved for a final decision on inclusion
based on pre-defined selection criteria. Studies were
selected if they reported accuracy of the index tests, com-
pared to histological examination of the lymph nodes
(reference standard) in women with a primary presenta-
tion of endometrial cancer of any histological type or
stage and allowed data extraction to create two by two
tables. No language restrictions were applied. In cases of
duplicate publications the most recent manuscript was
selected. Final inclusion or exclusion was decided after
examining the complete manuscripts. All were examined
in duplicate by the two reviewers with any discrepancies
resolved by a third reviewer (KSK).
A piloted data extraction form was used to collect infor-
mation on study characteristics, quality and accuracy
results from each of the selected manuscripts. The study
characteristics extracted were the stage of disease, the
index test and reference standard methodology and the
setting and date of the study. Accuracy data from the stud-
ies were reordered in two by two tables. For the purpose
of analysis when a manuscript reported the accuracy of
more than one index test, the tests were reported on sepa-
rately. Non diagnostic test results and a failure to perform
the test, such as an inability to detect the sentinel node or
inadequate histology were excluded from the two by two
tables, but their occurrence was recorded, along with the
results from the reference standard in each case, if pro-
vided.
Assessment of Study Quality
All of the manuscripts meeting the selection criteria were
assessed for their methodological quality, defined as the
confidence that the study design, conduct and analysis
minimised biases in the estimation of test accuracy. Exist-
ing, well developed tools were used to generate items for
our assessment of methodological quality [7-9], this proc-
ess was again carried out in duplicate. For the population,
consecutive or random recruitment of eligible women in
to the study was considered ideal. Convenience sampling,
such as arbitrary recruitment or non-consecutive recruit-
ment was deemed inadequate. Prospective recruitment of
patients was considered to be associated with potentially
a lesser degree of bias than retrospective recruitment. The
description of the population was considered ideal if the
study clarified the stage of disease and the body mass
index of a patient, which can affect the accuracy of tech-
niques. We recorded the stage of disease in accordanceBMC Women's Health 2008, 8:8 http://www.biomedcentral.com/1472-6874/8/8
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with FIGO classification. The reporting of the index test
was considered ideal if the study documented the test in
sufficient detail to allow replication by other researchers.
It was considered important for the time interval between
the index test and the reference standard to be described
and an interval of four or less weeks was considered suit-
able [10]. For the reference standard itself, a description of
method of histological verification was important and it
was considered preferable for the readers of the reference
standard to be blind to the index test results. Information
on the number of women recruited into the study and
those on whom outcome data were known was sought
from the manuscripts to examine partial and differential
verification. Verification was considered ideal if all
women originally enrolled into the study, without legiti-
mate exclusions were included in the data analysis. We
examined if withdraws from the study were explained and
if uninterpretable results were reported.
The main strengths and weaknesses in respect of each of
the above items for all studies included in the systematic
review were tabulated. We did not attempt to collapse our
assessment of quality into a score, as suggested methods
have little validity and may have a tendency to obscure the
strengths and weaknesses of a study rather than clarify
them.
Data synthesis
From the two by two tables, sensitivity (true positive rate)
and specificity (true negative rate), along with their exact
confidence intervals were computed. These estimates were
plotted in a ROC space to evaluate the degree of correla-
tion between these indices. When two by two tables con-
tained zero cells we applied a standard correction of
adding 0.5 to all four cells of that table [11].
We anticipated that in common with other diagnostic
reviews [10,12,13] there would be heterogeneity of results
amongst involved studies. We examined heterogeneity
visually using forest plots of sensitivity, specificity and LRs
and statistically using Cochran Q [14]. The small number
of studies did not allow for detailed exploration of rea-
sons for heterogeneity using meta regression techniques.
However studies were instead divided into index test type,
which in previous reviews has represented a major source
of heterogeneity [16] and difference in accuracy were
tested for statistical significance.
We used bivariate random-effect meta-analysis [16] to
obtain summary estimates of sensitivity and specificity
and other derived measures such as positive and negative
likelihood ratios (LRs). LRs allow estimation of the prob-
ability of lymphatic spread with a specific test result [17-
19]. The bivariate model assumes that logit transforma-
tions of sensitivity and specificity are negatively correlated
and follow a bivariate normal distribution. This analysis
also incorporates the different precision by which sensitiv-
ity and specificity have been measured in each study. The
model produces random effect estimations for the mean
logit sensitivity and specificity with corresponding 95%
confidence intervals, it produces also an estimation for
the amount of between-study variation for sensitivity and
specificity separately, and finally an estimation of the cov-
ariance between sensitivity and specificity. Confidence
regions in logit-ROC space can be constructed using these
estimates. The ellipse in logit-ROC space can be back-
transformed to conventional scale, and plotted in ROC
space giving a confidence region for the summary operat-
ing point.
Meta-DiSc version 1.4 [14] was used for initial analyses
and forest plots and the PROC MIXED procedure in SAS
version 8.2 for Windows (SAS Institute) was used to fit
bivariate models.
Results
A total of 18 manuscripts including 693 women with pri-
mary endometrial cancer were included in the review [20-
37] (Figure 1). There were 19 two by two tables evaluating
one of four index tests, there were no studies identified
that reported the accuracy of PET. A proportion of the
population (106/693, 15%) were included more than
once in 2/19 two by two tables. Table 1 and Figure 2 sum-
maries the salient features and quality of each of the stud-
ies. It is evident that there was a wide variation and
numerous deficiencies in the methodological quality of
the included studies.
Figure 3 show Forrest plots with sensitivities and specifici-
ties of individual studies according to index test. Table 2
shows pooled sensitivities and specificities for the various
index tests estimated by the bivariate analysis from which
we derived other measures such as positive and negative
likelihood ratios. Figure 4 shows the summary operating
estimates for the various index tests with corresponding
confidence ellipses. For each of the index tests variation in
sensitivity was much greater than specificity. MRI was the
most accurate index test while successful sentinel node
had similar results (Table 2). P-values of tests for compar-
ison between the three main diagnostic modalities are
shown in Table 2. CT was much less accurate in detection
of lymphatic spread (Table 2). There was only one study
that reported the accuracy of ultrasound scanning the
results of which were positive LR 50.3 and a negative LR
0.67, the presence of only one study makes it difficult to
draw a conclusion concerning this technique, other than
to note the sensitivity of the test (33%) was poor. The fail-
ure rate to detect the sentinel node ranged from 6.6% (1/
16 patients) to 100%.BMC Women's Health 2008, 8:8 http://www.biomedcentral.com/1472-6874/8/8
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Study selection process for systematic review of literature on accuracy of tests for lymph node metastasis in endometrial can- cer Figure 1
Study selection process for systematic review of literature on accuracy of tests for lymph node metastasis in endometrial can-
cer.
Potentially relevant studies 
identified and screened for retrieval 
from electronic search n=1406
Citations excluded at initially screening 
(inappropriate study design, population, test, 
reference standard)  n=1357
Studies retrieved for more detailed evaluation  n=49
Studies excluded after examination of full manuscript  n=32
• Review article or technique summary only n=12
•index test results not reported separately for our population n=1
•Inability to construct a 2 by 2 table n=9
•Index test not specific to lymph nodes n=2
•Duplicate publication n=1
•Letter only n=2
•Predictors for LN involvement only n=4
•Unable to determine index test used n=1
Studies included in review  n=18 *
•Sentinel node biopsy n=9
•Magnetic resonance imaging n=4
•Computer tomography n=5
•Ultra sound scan n=1
* One study evaluated more than one test
The reference list for excluded studies is available from the corresponding authorBMC Women's Health 2008, 8:8 http://www.biomedcentral.com/1472-6874/8/8
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Discussion
Our review showed that MRI and successful sentinel node
biopsy (sentinel node biopsy has a variable failure rate)
were the most accurate tests for predicting the lymph node
status of women with primary endometrial cancer. Other
tests were poor in accuracy. These results must be inter-
preted with caution as the quality of studies available for
review was variable, with many of poor methodological
quality that may result in the introduction of bias. This
review show an urgent need for the further high quality
primary studies that include the use of PET scanning as an
alternative test which may be beneficial.
This review provides a robust summary of the available
evidence to date and an example of the methodology
required to perform a review of diagnostic test accuracy.
We performed an extensive search for studies and used
well developed methods for quality assessment. The defi-
ciencies in quality made explicit by our review should
help improve further research in this area [7]. It is imper-
ative that the new STARD and QUADAS guidelines are fol-
lowed in the undertaking of such studies so that our
inference in the future can be based on high quality
review, reducing heterogeneity and the risk of bias.
Another criticism of our approach might be that in light of
the unexplained heterogeneity in the results, meta analy-
sis should perhaps have been avoided. We also accept that
we are combing results of tests over a wide time scale,
where the accuracy of the technique may have improved.
Also that the comparison of tests is an indirect one and
hence subject to bias, especially as there is a wide variation
in the spectrum of diseases that the different tests are used
in.
Our study shows that based on the currently available evi-
dence MRI is the most accurate tool to determine the
lymph node status of patients. It has the advantage of also
guiding the surgeon as to the depth of myometrial inva-
The quality of studies included in systematic review of literature on accuracy of tests for lymph node metastasis in endometrial  cancer Figure 2
The quality of studies included in systematic review of literature on accuracy of tests for lymph node metastasis in endometrial 
cancer. Stacked bar chart used. Numbers in bars indicate number of studies.
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Table 1: Diagnostic accuracy of tests to determine lymph node metatasis in primary endometrial cancer: study characteristics
Author and 
Index Test
Year Population Setting Index test and failure rate Reference Standard 
Histological method
SN
Burke TW 1996 15 women recruited 15 women had index test and reference standard 
Stage: not stated Pelvic and paraaortic selective lymphadenectomy Open 
surgery
Hospital – Not stated Country – USA Dates 
– not stated
SN biopsy using 3 mls blue dye injected into subserosal myometrium 
1 women unable to identify SN, positive lymph node status
Histological method not 
stated
Echt M 1999 8 women recruited 8 women had index test and 7 reference standard 
Advanced disease prevented lymphadenectomy Stage:IB Pelvic and 
paraaortic lymphadenectomy Open surgery
Hospital – Alton Ochsner Medical 
Foundation and University of South Florida 
Collage of Medicine Dates – 01/01/1993 – 
31/03/1995
SN biopsy using 2 mls blue dye injected into uterine funds In all 7 
women unable to identify SN, 1 women positive histology
Histological method not 
stated
Holub Z 2001 8 women recruited 8 women had index test and reference standard 
Stage:IA-1, IB-5, IC-1, IIIC-1 Pelvic lymphadenectomy Laparoscopic surgery
Hospital – Not stated Country – Czech 
Republic Dates – 01/200 – 11/2000
SN biopsy using 2 mls blue dye injected into subserosal myometrium 
3 women unable to identify SN, all women histology negative
Histological method not 
stated
Niikura H 2003 28 women recruited 28 women had index test and reference standard 
Stage: IA-7, IB-11, IIA-2, IIB-1, IIIA-1, IIIC-2 Pelvic and paraaortic 
lymphadenectomy Open surgery
Hospital – Tohoku University School of 
Medicine Country – Japan Dates – 06/01 – 
01/03
SN biopsy using 70 MBq technetium-99 m colloidal albumin injected 
hysteroscopically into endomertium 5 women unable to identify a SN, 
1 women positive histology
H and E staining and 
mmunohistochemistry
Pelosi E 2003 16 women recruited 16 women had index test and reference standard 
Stage: Ib-16 Pelvic lymphadenectomy Laparoscopic surgery
Hospital – Not stated Country – Italy Dates 
– 02/02 – 04/02
SN biopsy using 37 MBq technetium-99 m colloidal albumin and 4 ml 
blue dye injected into the cervix 1 women unable to identify SN, 
negative lymph node status
H and E staining and 
immunohistochemistry
Raspagliesi F 2003 18 women recruited18 women had index test14 women had reference 
standard4 excluded, 2 due to disease stageStage IA-4, IB-9, IIIA-1, IIIC-
4Pelvic lymphadenectomy in all women, paraaortic only if deemed 
necessaryOpen surgery
Hospital – Not statedCountry – ItalyDates – 
Not stated
SN biopsy using 111 MBq technetium-99 m colloidal albumin injected 
hysteroscopically into sub endomertium
H and E staining
Fersis N 2003 10 Women recruited 10 women had index test and reference standard 
Stage : Ib pelvic +/- paraaortic lymphadenectomy Open surgery
Hospital – Not stated Country – Germany 
Dates – Not stated
SN biopsy using 40–100 MBq technetium-99 m colloidal albumin 
injected hysteroscopically into tumour 3 patients unable to identify 
SN, patient's lymph node status was negative
Histological method not 
stated
Holub Z 2004 25 women recruited 25 women had index test and reference standard 
Stage: not stated Pelvic lymphadenectomy (yes patent had sampling only) 
Laparoscopic surgery
Hospital – Not stated Country – Czech 
Republic Dates – 02/00 – 08/03
SN using 5 ml blue dye injected into cervix and uterine fundus 4 
patients unable to identify SN, patients lymph node status was 
negative
Histological method not 
stated
Lelievre L 2004 12 women recruited 12 women had index test and reference standard 
Stage: Ib-2, Ic-5, IIa-1, IIb-1, IIIc-3 Pelvic lymphadenectomy Laparoscopic 
surgery
Hospital – Not stated Country – France 
Dates 01/02 – 12/02
SN biopsy using 120 MBq technetium-99 m colloidal albumin injected 
in to the cervix and 2 mls blue dye injected into the cervix 11 patients 
had SN identified using combined technique, 10 using technetium-99 
m alone and 9 using blue dye alone
H and E staining and 
immunohistochemistry
CT
Balfe DM 1983 61 women recruited 18 women had index test and reference standard 43 
women excluded without explanation Stage: not stated Pelvic and 
paraaortic lymphadenectomy Open surgery
Hospital – Mallinckrodt Institute of 
Radiology Country – USA Dates – 07/76 – 
07/81
CT using EMI CT500S and EMI 7070 3s scanners Lymph nodes > 10 
mm abnormal
Histological method not 
stated
Varpula MJ 1993 47 women recruited47 women had index test43 women had index test and 
reference standard, 4 women excluded as suitable for dxt onlyStage: I-36, II-
7Pelvic and paraaortic unilateral and bilateral clearance and samplingOpen 
surgery
Hospital – Not statedCountry – 
FinlandDates – 05/87 – 05/90
CT scan using Siemans Somatom CR/General Electric 9800 
scannerslymph nodes > 10 mm abnormal
Histological method not 
stated
La Fianza A 1997 125 women recruited 125 women index test and reference standard Stage: 
I-125, II-12, III-8 Pelvic lymphadenectomy Open surgery
Hospital – Not stated Country – Italy Dates 
– 01/1996 – 09/1993
CT using III generation Somatom 2, Somatome Plus and Siemens 
scanner
Histological method not 
stated
Conner JP 2000 702 women were eligible, 210 excluded follow up at another centre, 
secondary malignancy or no surgery planned 487 women excluded as no 
CT 75 women had index test 56 women had reference standard, 6 had no 
lymphadenectomy due to index test results, 13 no explanation Stage : I-350, 
II-73, III-49, IV-20 Pelvic and paraaortic lymph node sampling Open surgery
Hospital – University of Iowa Hospital and 
Clinics Country – USA Dates – 1979 – 1993
CT scanner model not stated Histological method not 
stated
Zerbe M 2000 54 women recruited 54 women index test 36 women reference standard, 
no explanation for exclusion Stage I–III Lymph node type not stated Surgery 
type not stated
Hospital – Baltimore Medical Centre 
Country – USA Dates – 01/90 – 12/98
CT scanner model not stated No definition for lymph node 
abnormality
Histological method not 
stated
USS
Sawicki W 2003 90 women recruited90 women had index test and reference standardStage 
– not statedlymph node type not statedSurgery type, not stated
Hospital – Not statedCountry – 
PolandDates – Not stated
USS either abdominal or transvaginal using Siemens Sonoline Versu 
Prox with a 6.5–7.5 MHZ probe for transvaginal and 3.5 MHZ probe 
for abdominal definition for lymph node abnormality
Histological method not 
stated
MRI
Hricak H 1991 20 women recruited 20 women had the index test and reference standard 
Stage: I-16, II-1, III-3 Pelvic lymph node sampling Open surgery
Hospital – Not stated Country – USA Dates 
– 01/02/89 – 01/12/89
MRI using 1.5T Sigma and 1.5T Magnetom scanner lymph nodes > 10 
mm abnormal
Histological method not 
stated
Varpula MJ 1993 46 women recruited 46 women had index test 43 women had the index 
test and reference standard, 3 excluded as suitable for DXT only Stage: I-
36, II-7 Pelvic and paraaortic unilateral and bilateral clearance and sampling 
Open surgery
Hospital – Not stated Country – Finland 
Dates – 05/87 – 05/90
MRI using < 0.05T Acut scanner Lymph nodes > 10 mm abnormal Histological method not 
stated
Taieb S 2002 86 women recruited 86 women had index test and reference standard 
Stage: Ia-24, Ib-26, Ic-14, IIa-2, Iib-2, IIIc-15, IVa-2, IVb-1 Pelvic and 
paraaortic lymphadenectomy Open surgery
Hospital – Not stated Country – France 
Dates – 01/97 – 03/02
MRI scanner type not stated Histological method not 
stated
Manfredi R 2004 37 women recruited 37 women had index test 21 women had reference 
standard, 16 women excluded as no lymph nodes were palpable Stage: Ia-2, 
Ib-20, Ic-15 Pelvic lymph node sampling in 11, pelvic and paraaortic 
lymphadenectomy in 10 Open surgery
Hospital – Not stated Country – Italy Dates 
– 06/97 – 02-01
MRI using 1.5T Echospeed, GE medical System scanner Lymph nodes 
abnormal > 10 mm
Histological method not 
stated
SN = sentinel node MRI = magnetic resonance imaging H and E staining = hematoxylin and eosin staining. CT = computer tomography USS = ultrasound scan.BMC Women's Health 2008, 8:8 http://www.biomedcentral.com/1472-6874/8/8
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sion and potential treatment required. Reviews of test
accuracy for lymphatic spread in other gynaecological
cancers have shown sentinel node biopsy to be the most
accurate test, as have studies in other cancers [15]. How-
ever this did not appear to be the case for endometrial can-
cer as MRI was marginally more accurate, although this
was not a statistically significant increase in accuracy over
sentinel node biopsy. There was a large variation in the
ability to detect the sentinel node. Although this usually
occurred in a small percentage of patients in the studies,
one study was unable to detect the node in any of its
patients [21]. This may have been due the different tech-
nique used and the reliance on only blue dye to detect the
node (Table I).
The debate regarding the necessity of lymphadenectomy
in these patients led to the Medical Research Council
funded ASTEC (a study in the treatment of endometrial
cancer) trial. One of the study's primary aims is to assess
the benefit, or otherwise of pelvic lymphadenectomy in
patients where disease is thought to be confined to the
corpus. Recruitment for this trial had now closed and the
preliminary results were presented at European Society of
Gynaecological Oncology in 2005. They suggested that
there was no benefit for survival or prevention of recur-
rence in performing lymphadenectomy for early stage
endometrial cancer. If this is confirmed in the final publi-
cation of the trial then it adds further importance to the
use of a non invasive assessment of lymph node status
Forrest plots of sensitivity and specificity for the various index tests Figure 3
Forrest plots of sensitivity and specificity for the various index tests. A. Sentinel node biopsy B. CT scanning C. MRI.
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which would allow a decision to be made on the require-
ment of adjuvant surgery, which in light of this trial will
be the only potential benefit of lymphadenectomy.
Conclusion
Independent of the results of ASTEC there are still benefits
in accurately being able to use a non or minimally inva-
sive technique to predict the lymph node status of patients
with primary endometrial cancer. This systematic review
of the available evidence suggests that MRI is the most
accurate method to do this, however one should be cau-
tious in interpreting the results in view of the number and
heterogeneity of the studies available and the large confi-
dence intervals of results. Further high quality studies are
required to look at the real potential both of this and
other imaging modalities such as PET.
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